vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and N-able, Inc. (NABL). Click either name above to swap in a different company.
N-able, Inc. is the larger business by last-quarter revenue ($130.3M vs $86.8M, roughly 1.5× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 11.8%). N-able, Inc. produced more free cash flow last quarter ($20.9M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 7.0%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Able UK is a British industrial services company specialising in decommissioning of ships and offshore installations.
IOVA vs NABL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $130.3M |
| Net Profit | — | — |
| Gross Margin | 67.4% | 76.2% |
| Operating Margin | -84.7% | 10.2% |
| Net Margin | — | — |
| Revenue YoY | 17.7% | 11.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $130.3M | ||
| Q3 25 | $67.5M | $131.7M | ||
| Q2 25 | $60.0M | $131.2M | ||
| Q1 25 | $49.3M | $118.2M | ||
| Q4 24 | $73.7M | $116.5M | ||
| Q3 24 | $58.6M | $116.4M | ||
| Q2 24 | $31.1M | $119.4M | ||
| Q1 24 | $715.0K | $113.7M |
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | $1.4M | ||
| Q2 25 | $-111.7M | $-4.0M | ||
| Q1 25 | $-116.2M | $-7.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | $10.8M | ||
| Q2 24 | $-97.1M | $9.5M | ||
| Q1 24 | $-113.0M | $7.5M |
| Q4 25 | 67.4% | 76.2% | ||
| Q3 25 | 43.0% | 77.5% | ||
| Q2 25 | 5.5% | 78.1% | ||
| Q1 25 | -0.8% | 76.6% | ||
| Q4 24 | 68.7% | 80.0% | ||
| Q3 24 | 46.2% | 82.9% | ||
| Q2 24 | -0.8% | 84.0% | ||
| Q1 24 | — | 83.9% |
| Q4 25 | -84.7% | 10.2% | ||
| Q3 25 | -140.7% | 8.8% | ||
| Q2 25 | -189.8% | 7.7% | ||
| Q1 25 | -245.8% | 1.5% | ||
| Q4 24 | -117.5% | 13.7% | ||
| Q3 24 | -152.1% | 20.5% | ||
| Q2 24 | -327.6% | 18.4% | ||
| Q1 24 | -16464.6% | 18.0% |
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | 1.1% | ||
| Q2 25 | -186.2% | -3.1% | ||
| Q1 25 | -235.5% | -6.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | 9.2% | ||
| Q2 24 | -312.2% | 7.9% | ||
| Q1 24 | -15800.8% | 6.6% |
| Q4 25 | — | $-0.04 | ||
| Q3 25 | — | $0.01 | ||
| Q2 25 | $-0.33 | $-0.02 | ||
| Q1 25 | $-0.36 | $-0.04 | ||
| Q4 24 | $-0.24 | $0.01 | ||
| Q3 24 | $-0.28 | $0.06 | ||
| Q2 24 | $-0.34 | $0.05 | ||
| Q1 24 | $-0.42 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $111.8M |
| Total DebtLower is stronger | — | $393.9M |
| Stockholders' EquityBook value | $698.6M | $804.7M |
| Total Assets | $913.2M | $1.4B |
| Debt / EquityLower = less leverage | — | 0.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $111.8M | ||
| Q3 25 | $300.8M | $101.4M | ||
| Q2 25 | $301.2M | $93.9M | ||
| Q1 25 | $359.7M | $94.1M | ||
| Q4 24 | $323.8M | $85.2M | ||
| Q3 24 | $397.5M | $174.4M | ||
| Q2 24 | $412.5M | $157.5M | ||
| Q1 24 | $356.2M | $139.2M |
| Q4 25 | — | $393.9M | ||
| Q3 25 | — | $331.7M | ||
| Q2 25 | — | $332.1M | ||
| Q1 25 | — | $332.6M | ||
| Q4 24 | — | $333.1M | ||
| Q3 24 | — | $333.6M | ||
| Q2 24 | — | $334.1M | ||
| Q1 24 | — | $334.5M |
| Q4 25 | $698.6M | $804.7M | ||
| Q3 25 | $702.3M | $813.4M | ||
| Q2 25 | $698.5M | $809.4M | ||
| Q1 25 | $767.9M | $775.1M | ||
| Q4 24 | $710.4M | $759.3M | ||
| Q3 24 | $773.5M | $765.0M | ||
| Q2 24 | $768.5M | $724.4M | ||
| Q1 24 | $680.0M | $709.1M |
| Q4 25 | $913.2M | $1.4B | ||
| Q3 25 | $904.9M | $1.4B | ||
| Q2 25 | $907.4M | $1.4B | ||
| Q1 25 | $966.7M | $1.4B | ||
| Q4 24 | $910.4M | $1.3B | ||
| Q3 24 | $991.1M | $1.2B | ||
| Q2 24 | $964.3M | $1.2B | ||
| Q1 24 | $869.8M | $1.1B |
| Q4 25 | — | 0.49× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.44× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.46× | ||
| Q1 24 | — | 0.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $25.3M |
| Free Cash FlowOCF − Capex | $-61.9M | $20.9M |
| FCF MarginFCF / Revenue | -71.3% | 16.0% |
| Capex IntensityCapex / Revenue | 10.7% | 3.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $75.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $25.3M | ||
| Q3 25 | $-78.7M | $24.0M | ||
| Q2 25 | $-67.4M | $24.2M | ||
| Q1 25 | $-103.7M | $19.7M | ||
| Q4 24 | $-73.3M | $26.0M | ||
| Q3 24 | $-59.0M | $22.0M | ||
| Q2 24 | $-98.4M | $27.3M | ||
| Q1 24 | $-122.3M | $4.2M |
| Q4 25 | $-61.9M | $20.9M | ||
| Q3 25 | $-89.5M | $17.4M | ||
| Q2 25 | $-74.9M | $20.4M | ||
| Q1 25 | $-109.9M | $16.4M | ||
| Q4 24 | $-77.5M | $18.8M | ||
| Q3 24 | $-61.3M | $18.2M | ||
| Q2 24 | $-98.9M | $24.0M | ||
| Q1 24 | $-126.5M | $746.0K |
| Q4 25 | -71.3% | 16.0% | ||
| Q3 25 | -132.7% | 13.2% | ||
| Q2 25 | -124.9% | 15.5% | ||
| Q1 25 | -222.8% | 13.9% | ||
| Q4 24 | -105.1% | 16.2% | ||
| Q3 24 | -104.6% | 15.7% | ||
| Q2 24 | -317.9% | 20.1% | ||
| Q1 24 | -17685.3% | 0.7% |
| Q4 25 | 10.7% | 3.4% | ||
| Q3 25 | 16.1% | 5.0% | ||
| Q2 25 | 12.4% | 2.9% | ||
| Q1 25 | 12.6% | 2.8% | ||
| Q4 24 | 5.7% | 6.1% | ||
| Q3 24 | 3.9% | 3.2% | ||
| Q2 24 | 1.4% | 2.7% | ||
| Q1 24 | 583.4% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 17.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.04× | ||
| Q2 24 | — | 2.89× | ||
| Q1 24 | — | 0.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
NABL
| Transferred Over Time | $121.9M | 94% |
| Transferred At Point In Time | $8.4M | 6% |
| Other Revenue | $1.3M | 1% |
